UPDATE 1-Drug developer GW Pharma to cancel London listing
October 19, 2016 at 03:50 AM EDT
Oct 19 (Reuters) - Britain's GW Pharmaceuticals Plc , a developer of marijuana-based epilepsy treatments, said it planned to cancel its listing in London's junior market and would retain listing of its American Depositary Receipts (ADRs) on Nasdaq to simplify trading and cut expenses of dual listing.